- Home
- CVKD vs SBFM Comparison
CVKD vs SBFM Comparison
Compare CVKD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- SBFM
- Stock Information
- Founded
- CVKD 2022
- SBFM 2006
- Country
- CVKD United States
- SBFM United States
- Employees
- CVKD N/A
- SBFM N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- SBFM Health Care
- Exchange
- CVKD Nasdaq
- SBFM Nasdaq
- Market Cap
- CVKD 17.1M
- SBFM 3.7M
- IPO Year
- CVKD 2023
- SBFM N/A
- Fundamental
- Price
- CVKD $15.24
- SBFM $3.06
- Analyst Decision
- CVKD Strong Buy
- SBFM
- Analyst Count
- CVKD 2
- SBFM 0
- Target Price
- CVKD $52.50
- SBFM N/A
- AVG Volume (30 Days)
- CVKD 59.6K
- SBFM 121.6K
- Earning Date
- CVKD 11-08-2024
- SBFM 11-11-2024
- Dividend Yield
- CVKD N/A
- SBFM N/A
- EPS Growth
- CVKD N/A
- SBFM N/A
- EPS
- CVKD N/A
- SBFM N/A
- Revenue
- CVKD N/A
- SBFM $30,481,982.00
- Revenue This Year
- CVKD N/A
- SBFM $86.70
- Revenue Next Year
- CVKD N/A
- SBFM $126.76
- P/E Ratio
- CVKD N/A
- SBFM N/A
- Revenue Growth
- CVKD N/A
- SBFM 109.82
- 52 Week Low
- CVKD $5.40
- SBFM $2.42
- 52 Week High
- CVKD $32.55
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- CVKD 60.90
- SBFM 49.32
- Support Level
- CVKD $11.19
- SBFM $2.85
- Resistance Level
- CVKD $15.93
- SBFM $3.05
- Average True Range (ATR)
- CVKD 1.36
- SBFM 0.15
- MACD
- CVKD 0.23
- SBFM 0.02
- Stochastic Oscillator
- CVKD 61.01
- SBFM 63.89
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.